Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism
Natasha A. Trzaskalski, Evgenia Fadzeyeva, Erin E. Mulvihill
Clinical Medicine Insights Endocrinology and Diabetes (2020) Vol. 13, pp. 117955142091297-117955142091297
Open Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

Trends in insulin resistance: insights into mechanisms and therapeutic strategy
Mengwei Li, Xiaowei Chi, Ying Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 394
Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19
Sebastiano Bruno Solerte, Antonio Di Sabatino, Massimo Galli, et al.
Acta Diabetologica (2020) Vol. 57, Iss. 7, pp. 779-783
Open Access | Times Cited: 198
Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways
Nami Lee, Yu Jung Heo, Sung‐E Choi, et al.
Journal of Immunology Research (2021) Vol. 2021, pp. 1-11
Open Access | Times Cited: 100
Neuropeptide Y Is an Immunomodulatory Factor: Direct and Indirect
Wei-can Chen, Yibin Liu, Weifeng Liu, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 80
TNF‐α/IFN‐γ synergy amplifies senescence‐associated inflammation and SARS‐CoV‐2 receptor expression via hyper‐activated JAK/STAT1
Renuka Kandhaya‐Pillai, Xiaomeng Yang, Tamar Tchkonia, et al.
Aging Cell (2022) Vol. 21, Iss. 6
Open Access | Times Cited: 63
COVID-19: Diabetes Perspective—Pathophysiology and Management
Siva Dallavalasa, SubbaRao V. Tulimilli, Prakash Janhavi, et al.
Pathogens (2023) Vol. 12, Iss. 2, pp. 184-184
Open Access | Times Cited: 24
DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson’s disease
Seong‐Jin Yu, Yun Wang, Hui Shen, et al.
GeroScience (2024) Vol. 46, Iss. 5, pp. 4349-4371
Open Access | Times Cited: 10
DPP-4 inhibitors may improve the mortality of coronavirus disease 2019: A meta-analysis
Yan Yang, Zixin Cai, Jingjing Zhang
PLoS ONE (2021) Vol. 16, Iss. 5, pp. e0251916-e0251916
Open Access | Times Cited: 48
Macrophage Responses to Environmental Stimuli During Homeostasis and Disease
Adil Rasheed, Katey J. Rayner
Endocrine Reviews (2021) Vol. 42, Iss. 4, pp. 407-435
Open Access | Times Cited: 41
Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
Alba Sebastián-Martín, Belén G. Sánchez, José María Mora-Rodríguez, et al.
Biomedicines (2022) Vol. 10, Iss. 8, pp. 2026-2026
Open Access | Times Cited: 31
COVID-19: is there a link between the course of infection and pharmacological agents in diabetes?
Tiziana Filardi, Susanna Morano
Journal of Endocrinological Investigation (2020) Vol. 43, Iss. 8, pp. 1053-1060
Open Access | Times Cited: 48
Circulating levels of soluble Dipeptidylpeptidase-4 are reduced in human subjects hospitalized for severe COVID-19 infections
Kristina Schlicht, Nathalie Rohmann, Corinna Geisler, et al.
International Journal of Obesity (2020) Vol. 44, Iss. 11, pp. 2335-2338
Open Access | Times Cited: 39
Perspectives of Antidiabetic Drugs in Diabetes With Coronavirus Infections
Bao Sun, Shiqiong Huang, Jiecan Zhou
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 34
Generation, characterization and molecular binding mechanism of novel dipeptidyl peptidase-4 inhibitory peptides from sorghum bicolor seed protein
Abdul Majid, M. Lakshmikanth, N.K. Lokanath, et al.
Food Chemistry (2021) Vol. 369, pp. 130888-130888
Closed Access | Times Cited: 34
DPP4 as a Potential Candidate in Cardiovascular Disease
Siyu Chen, Kong Xiangquan, Ke-Fan Zhang, et al.
Journal of Inflammation Research (2022) Vol. Volume 15, pp. 5457-5469
Open Access | Times Cited: 23
Milk protein digestion and the gut microbiome influence gastrointestinal discomfort after cow milk consumption in healthy subjects
Silvia Tagliamonte, Roberta Barone Lumaga, Francesca De Filippis, et al.
Food Research International (2023) Vol. 170, pp. 112953-112953
Open Access | Times Cited: 13
COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery
Sunny Kumar, Malini Basu, Pratyasha Ghosh, et al.
Genes & Diseases (2023) Vol. 10, Iss. 4, pp. 1402-1428
Open Access | Times Cited: 12
Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes
Xianyu Zhang, Jian Jiang, Jiajia Xu, et al.
BMC Musculoskeletal Disorders (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 4
Inhibiting DPP4 activity protects hiPSC-derived steatotic HLCs by supporting fatty acid and purine metabolism and dampening inflammation
Christiane Lörch, Wasco Wruck, R. J. Julian, et al.
Research Square (Research Square) (2025)
Open Access
Inflammatory Bowel Disease in a Patient Returning from Colombia: Association with Dipeptidyl Peptidase 4 Inhibitor?
Ahmed B. Bayoumy, Gwen Masclee, Nanne K.H. de Boer, et al.
Case Reports in Gastroenterology (2025) Vol. 19, Iss. 1, pp. 89-95
Open Access
Vegetal oil-based ketogenic diet improves inflammation and fibrosis in experimental metabolic dysfunction-associated steatohepatitis
Alessia Provera, Naresh Naik Ramavath, Laila Lavanya Gadipudi, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Circadian Rhythm in Adipose Tissue: Novel Antioxidant Target for Metabolic and Cardiovascular Diseases
Andy W. C. Man, Ning Xia, Huige Li
Antioxidants (2020) Vol. 9, Iss. 10, pp. 968-968
Open Access | Times Cited: 29
New quinoxaline compounds as DPP-4 inhibitors and hypoglycemics: design, synthesis, computational and bio-distribution studies
Yasmin M. Syam, Manal M. Anwar, Somaia S. Abd El‐Karim, et al.
RSC Advances (2021) Vol. 11, Iss. 58, pp. 36989-37010
Open Access | Times Cited: 25
Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance
Ashwani Sharma, Tarun Virmani, A. Sharma, et al.
Diabetes Metabolic Syndrome and Obesity (2022) Vol. Volume 15, pp. 1845-1864
Open Access | Times Cited: 18
Optical genome mapping identifies rare structural variations as predisposition factors associated with severe COVID-19
Nikhil Sahajpal, Chi-Yu Jill Lai, Alex Hastie, et al.
iScience (2022) Vol. 25, Iss. 2, pp. 103760-103760
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top